The company cites order timing delays for a $0.03 per share loss despite a record backlog and upcoming conformal battery shipments.
Ultralife Corporation posted Q1 2026 revenue of $47.4 million, missing expectations due to shipment delays and order timing. The company reported a $0.2 million operating loss, equating to a $0.03 per share loss.
The firm highlighted a record $115.1 million backlog, driven by demand for its conformal wearable batteries. Management targets $8 million in shipments of these batteries by mid-2026, aiming to address scrap-related production issues by midyear.
Shares showed muted reaction in after-hours trading as investors weighed near-term losses against long-term backlog growth.